You just read:

U.S. FDA Grants Priority Review to Bayer's Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases

News provided by

Bayer HealthCare Pharmaceuticals Inc.

Feb 13, 2013, 01:00 ET